Biotech Values

[zipjet]

people are starting to realize that long-term opportunity in this space is limited.

The incidence rate for HCV collapsed long ago and remains low in the developed* world. Even the prevalence is dropping as older infected die off. There will be a bolus to treat in the west* where pricing will allow nice profits for the drug companies.

But how long will that last? Given the short life, how will the revenues/profits be valued?



http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm


* I understand that there are parts of the world where HCV incidence is still high. But those are also places where high-priced treatments will not work well.